A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

NCT05523596 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-04-16

No results posted yet for this study

Summary

A Phase 1 Non-Randomized Open Label Study of Oral ICM20

Conditions

  • Safety Issues

Interventions

DRUG

ICM20

small molecules

DRUG

Benznidazole

small molecule

Sponsors & Collaborators

  • IC-MedTech Corporation

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-20
Primary Completion
2025-10-03
Completion
2025-10-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523596 on ClinicalTrials.gov